4//SEC Filing
Issa Mohamed Khairie 4
Accession 0000879169-25-000090
CIK 0000879169other
Filed
Jul 16, 8:00 PM ET
Accepted
Jul 17, 4:04 PM ET
Size
10.0 KB
Accession
0000879169-25-000090
Insider Transaction Report
Form 4
INCYTE CORPINCY
Issa Mohamed Khairie
EVP, Head of US Oncology
Transactions
- Award
Performance Shares
2025-07-15+21,923→ 21,923 totalExp: 2028-07-15→ Common Stock (21,923 underlying) - Award
Common Stock
2025-07-15+8,769→ 85,252 total - Award
Employee Stock Option (right to buy)
2025-07-15+19,735→ 19,735 totalExercise: $68.25Exp: 2035-07-14→ Common Stock (19,735 underlying)
Footnotes (4)
- [F1]Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
- [F2]Including the July 15, 2025 grant, this includes an aggregate of 85,252 shares of common stock issuable pursuant to previously reported RSUs that have not vested.
- [F3]Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
- [F4]The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years.
Documents
Issuer
INCYTE CORP
CIK 0000879169
Entity typeother
Related Parties
1- filerCIK 0002050035
Filing Metadata
- Form type
- 4
- Filed
- Jul 16, 8:00 PM ET
- Accepted
- Jul 17, 4:04 PM ET
- Size
- 10.0 KB